Specialty drugs are biologics—"drugs derived from living cells"—that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions like cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease, and hepatitis C. Specialty drugs are often biologics—"drugs derived from living cells"—that are oral medications. As soon as possible, patients should receive the right medicine. Some businesses have personalized treatment groups that are obviously highly passionate about the topic, even though they may go by the moniker "advances in genetic organizations" or "stratified medicine" groups. However, recent research that looked into the worldwide drug pipeline inventory of around 20 large businesses found that relatively few of them had what may be called stratified or customized medication. We have been striving to put that framework in place. Personalized medicine concepts have been or are now being included within early drug development advice, which will eventually be used to affect policy on patient screening or clinical trial strategies in later phases.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Lan Wang
Paretor LLC, United States
Maria Cristina Gamberini
University of Modena and Reggio Emilia, Italy
Lucas Amaral Machado
University of Sao Paulo State – UNESP, Brazil
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, IndiaSubmit your abstract Today
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil